A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Spreafico, A., Janku, F., Rodon, J.A., Tolcher, A.W., Chandana, S.R., Oliva, M., Musalli, S., Knauss, L., Kragh, M., Alifrangis, L., Fröhlich, C., Melander, M.C., Blondal, T., Pedersen, M.W., Lantto, J., Wood, D., Nadler, P.I., Horak, I.D., Siu, L.L., Lakhani, N.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1197P - A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Spreafico, A., Janku, F., Rodon, J.A., Tolcher, A.W., Chandana, S.R., Oliva, M., Musalli, S., Knauss, L., Kragh, M., Alifrangis, L., Fröhlich, C., Melander, M.C., Blondal, T., Pedersen, M.W., Lantto, J., Wood, D., Nadler, P.I., Horak, I.D., Siu, L.L., Lakhani, N.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Spreafico, A, Janku, F, Rodon, J A, Tolcher, A W, Chandana, S R, Oliva, M, Musalli, S, Knauss, L, Kragh, M, Alifrangis, L, Fröhlich, C, Melander, M C, Blondal, T, Pedersen, M W, Lantto, J, Wood, D, Nadler, P I, Horak, I D, Siu, L L, Lakhani, N
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article